[1] PAUL S M, MYTELKA D S, DUNWIDDIE C T, et al.  How to improve R&D productivity: The pharmaceutical industry's grand challenge[J]. Nature Reviews Drug Discovery, 2010, 9: 203-214.   doi: 10.1038/nrd3078
[2] AVORN J.  The $2.6 billion pill - methodologic and policy considerations[J]. New England Journal of Medicine, 2015, 372: 1877-1879.   doi: 10.1056/NEJMp1500848
[3] BOHM H J.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors[J]. Journal of Computer-Aided Molecular Design, 1992, 6: 61-78.   doi: 10.1007/BF00124387
[4] DOUGUETD, MUNIER-LEHMANN H, LABESSE, G, et al.  LEA3D: A computer-aided ligand design for structure-based drug design[J]. Journal of Medicinal Chemistry, 2005, 48: 2457-2468.   doi: 10.1021/jm0492296
[5]

WANG R, GAO Y, LAI L. LigBuilder: A multi-purpose program for structure-based drug design[J]. Journal of Molecular Modeling. 2000, 6: 498-516.

[6]

YUAN Y, PEI J, LAI L. Ligbuilder2: A practical de novo drug design approach[J]. Journal of Chemical Information and Modeling, 2001, 51(5): 1083-1091.

[7] NADERI M, ALVIN C, DING Y, et al.  A graph-based approach to construct target-focused libraries for virtual screening[J]. Journal of Cheminformatics, 2016, (8): 14-.   doi: 10.1186/s13321-016-0126-6
[8] NISHIBATA Y, ITAI A.  Automatic creation of drug candidate structures based on receptor structure[J]. Tetrahedron, 1991, 47(43): 8985-8990.   doi: 10.1016/S0040-4020(01)86503-0
[9] GITLLET V, JOHNSON A P, MATA P, et al.  SPROUT: A program for structure generation[J]. Journal of Computer-Aided Molecular Design, 1993, 7: 127-153.   doi: 10.1007/BF00126441
[10] BROWN N, MCKAY B, GILARDONI F, et al.  A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules[J]. Journal of Chemical Information and Computer Sciences, 2004, 44(30): 1079-1087.   doi: 10.1021/ci034290p
[11] FECHNER U, SCHNEIDER G.  Flux (2): Comparison of molecular mutation and crossover operators for ligand-based de novo design[J]. Journal of Chemical Information and Modeling, 2007, 47(2): 656-667.   doi: 10.1021/ci6005307
[12] TAIRAN L, MISAGH N, Chris A, et al.  Break down in order to build up: Decomposing small molecules for fragment-based drug design with eMolFrag[J]. Journal of Chemical Information and Modeling, 2017, 57(4): 627-631.   doi: 10.1021/acs.jcim.6b00596
[13] GHERSI D, SINGH M.  molBLOCKS: Decomposing small molecule sets and uncovering enriched fragments[J]. BioinFormatics, 2014, 30(14): 2081-2083.   doi: 10.1093/bioinformatics/btu173
[14]

MARTIN S, ANDY V. Scaffold Hopping in Medicinal Chemistry [M/oL]. Wiley Online Library, NATHAN, B. 2013 [2020]. https://onlinelibrary.wiley.com/doi/book/10.1002/9783527665143.

[15]

Landrum G A. RDKit: Cheminformatics and Machine Learning Software. GREG, L. (www.rdkit.org) [20200522]. www.rdkit.org.

[16]

LI S, XU H, CUI S, et al. Discovery and rational design of natural-product-derived 2-phenyl-3, 4-dihydro-2H-benzo [f] chromen-3-amine analogs as novel and potent dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes[J]. Journal of Medicinal Chemistry, 2016, 59 (14): 6772-6790. jmedchem.6b00505.

[17]

LI S, QIN C, CUI S, et al. Discovery of a natural-product-derived preclinical candidate for once-weekly treatment of type 2 diabetes[J]. Journal of Medicinal Chemistry, 2019, 62 (5): 2348-2361.

[18] LIU X, JIANG H, LI H.  SHAFTS: A Hybrid approach for 3D molecular similarity calculation: 1. Method and assessment of virtual screening[J]. Journal of Chemical Information and Modeling, 2011, 51(9): 2372-2385.   doi: 10.1021/ci200060s
[19] KOTALAR P R, BELLA J, OLSON N H, et al.  Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor[J]. The EMBO Journal, 1999, 18: 6249-6259.   doi: 10.1093/emboj/18.22.6249
[20] JOHNSON T W, Richardson P F, BAILEY S, et al.  Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-5-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno)pyrazolo[4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations[J]. Journal of Medicinal Chemistry, 2014, 57(11): 4720-4744.   doi: 10.1021/jm500261q